Clinical Trial: JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer

U.S., Sept. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07797153) titled 'JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer' on Aug. 25.

Brief Summary: This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN033 versus investigator's choice of chemotherapy in patients with recurrent or metastatic cervical cancer who have failed platinum-based chemotherapy and PD-1/L1 inhibitor therapy.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Recurrent or Metastatic Cervical Cancer

Intervention: DRUG: JSKN033

JSKN033 should be administered subcutaneously

DRUG: Docetaxel

Docetaxel

DRUG: ...